Strong Growth in QUVIVIQ Sales
Idorsia Ltd has reported impressive global net sales for QUVIVIQ (daridorexant), achieving more than a 130% increase year-on-year, amounting to CHF 91 million for the first nine months of 2025. This outstanding performance is a crucial step forward on Idorsia's journey to achieving profitability.
Expanding Commercial Portfolio
Idorsia's ambition extends beyond just QUVIVIQ. They are also focused on Aprocitentan (TRYVIO/JERAYGO), which is recognized as the first dual endothelin receptor antagonist indicated for systemic hypertension. The inclusion of this medication in the ACC/AHA Hypertension Management Guidelines emphasizes its significance in the market. The company has reaffirmed its sales guidance for QUVIVIQ, expecting to reach approximately CHF 130 million by the end of the fiscal year.
Insights From Leadership
CEO Srishti Gupta highlighted the company's strategic focus during her initial 100 days in the role. She emphasized supporting commercial teams to enhance QUVIVIQ's market performance while navigating the path for TRYVIO's market introduction. Gupta expressed satisfaction with the progress made across the board, particularly regarding increased sales and reduced operating expenses. Idorsia’s financial turnaround is a notable achievement, reflecting the commitment and efforts of the team and the supportive investors behind the company.
Research and Development Updates
In addition to their commercial advancements, Idorsia has been active in research and development. They are currently conducting a pediatric study on daridorexant, targeting patients with autism and ADHD, and expect to complete recruitment soon. Furthermore, positive results from a long-term study on Lucerastat in Fabry disease provide encouraging data suggesting potential kidney function improvements along with safety and tolerability.
Emerging Therapeutic Areas
Idorsia is not just looking back at successful products but is also laying the groundwork for future innovations. Early results from a Phase 1 clinical trial of their synthetic glycan vaccine platform, targeting C. difficile, demonstrate good tolerability and immunogenicity, with an anticipated progression to higher-dose cohorts. This showcases Idorsia's commitment to addressing significant healthcare challenges through innovative solutions.
Financial Performance Highlights
Idorsia's financial performance reflects a significant leap compared to the prior year. The company's net revenue for the first nine months of 2025 totaled CHF 173 million, which includes CHF 92 million from product sales and CHF 78 million stemming from contract revenues. This marks a robust increase from CHF 53 million during the same period in 2024.
Decrease in Operating Expenses
Operating expenses also saw a notable decline, from CHF 211 million in the first nine months of 2024 to CHF 162 million in 2025. This reduction underscores Idorsia's commitment to maintaining fiscal discipline while advancing its mission to bring innovative treatments to market. The net loss for the period was recorded at CHF 34 million, significantly improved from CHF 79 million in the previous year, marking a positive trend in the company's financial trajectory.
Outlook for the Future
Idorsia's outlook is filled with potential as they aim for continued growth. With a firm commitment to reaching profitability by the end of 2027, the company has extended its operating cash runway well into 2028, supported by CHF 65.6 million financing attracted from top-tier institutional investors. This financial backing underscores investor confidence in Idorsia's strategy and vision.
Frequently Asked Questions
What is the primary product driving Idorsia's sales growth?
The primary product driving sales growth for Idorsia is QUVIVIQ (daridorexant), which has seen a remarkable increase in sales of over 130% year-on-year.
When does Idorsia anticipate achieving profitability?
Idorsia aims to achieve profitability by the end of 2027, supported by its growing sales and disciplined expense management.
What strategic initiatives has Idorsia's CEO implemented?
CEO Srishti Gupta has focused on driving QUVIVIQ’s growth and advancing the company's research pipeline while ensuring financial stability.
How did Idorsia's net revenue for 2025 compare to 2024?
Idorsia reported a net revenue of CHF 173 million for the first nine months of 2025, a significant increase from CHF 53 million in the same period of 2024.
What is Idorsia's strategy for expanding its product portfolio?
Idorsia's strategy includes launching TRYVIO for hypertension and ongoing research across various therapeutic areas to introduce innovative treatments.
